News
ALPHA MOS : RESULTATS SEMESTRIELS 2017
Au cours de sa réunion du 11 septembre 2017, le Conseil d'administration d'Alpha MOS (Euronext Paris - Compartiment C - Code ISIN : FR0000062804-ALM) a arrêté les comptes semestriels 2017,....
ALPHA MOS : MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2017
Alpha MOS (Euronext Paris - Compartiment C - Code ISIN : FR0000062804-ALM) annonce, ce jour, avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers (AMF)....
Is Intrexon Corporation Stock Now a Bargain?
According to data from S&P Global Market Intelligence , Intrexon Corporation (NYSE: XON), a synthetic biology company, saw its shares dip by 7.72% last month. The company's shares struggled....
Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
Regeneron Pharmaceuticals (NASDAQ: REGN) unveiled phase 3 study data for its autoimmune disease drug Dupixent earlier this week that show it is effective in treating asthma. The success has....
5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing
What's the best dividend stock in all of big pharma? I would argue that the hands-down winner is AbbVie (NYSE: ABBV). The big biotech has the total package for dividend-seeking investors: a high....
Is the Sell-Off of Intercept Pharmaceuticals Stock Overblown?
Last year, a letter written by Chinese scholar Zeng Gong in 1080 sold for more than $30 million. It became the world's most expensive letter. However, a letter issued by Intercept Pharmaceuticals....
Why Shares of ImmunoGen, Inc. Sank Today
Shares of ImmunoGen (NASDAQ: IMGN) closed down 10.6% on Tuesday after the company disclosed that it exchanged some of its 4.5% convertible senior notes due in 2021 for newly issued shares.The....
Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy?
Shares of Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biotech, dropped by 13.69% today, after the company reported that its experimental treatment for super-refractory status epilepticus....
3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
It's been a great 2017 for Amgen (NASDAQ: AMGN) shareholders so far. Amgen stock is up close to 30%. The company announced several positive developments from its pipeline. Still, though, some....
Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today
Shares of Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotech developing novel cancer immunotherapies, are sinking after the company provided a business update along with a third-quarter....
2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term
There's a lot for investors to really like about Vertex Pharmaceuticals (NASDAQ: VRTX). The company reached profitability earlier this year. It has reported a string of positive clinical results....
5 Things Regeneron's CEO Said as the Biotech Stock Sank
Regeneron (NASDAQ: REGN) CEO Leonard Schleifer was on the hot seat Monday at the Morgan Stanley healthcare conference. And the timing was either terrific or terrible, depending on your....
3 Stocks for Future Millionaires
If you have a desire to be a millionaire someday -- I mean, come on, you're reading about investing. Of course, you're interested -- then one of the best ways to get there is to invest in great....
Why Teva Pharmaceutical Industries, MercadoLibre, and XL Group Jumped Today
The stock market soared on Monday, with major benchmarks finishing higher by 1% or more following a weekend that featured somewhat less devastation than many had feared. Hurricane Irma spent most....
Why Equifax, Regeneron Pharmaceuticals, and AngloGold Ashanti Slumped Today
Monday was a good day for the stock market, with most investors breathing a big sigh of relief despite the devastation that Hurricane Irma caused in the Southeastern U.S. over the weekend. Irma....
Why Achillion Pharmaceuticals Crashed 22.2% Today
After Johnson & Johnson (NYSE: JNJ) announced it's ending its agreement to develop Achillion Pharmaceuticals' (NASDAQ: ACHN) hepatitis C drugs, Achillion Pharmaceuticals shares lost 22.2% of....
Why Teva Pharmaceutical Industries Ltd. (ADR) Is Soaring
After announcing that it has officially filled its vacant CEO seat, Teva Pharmaceutical Industries (NYSE: TEVA), a pharma company primarily focused on generic drugs, jumped 18% as of 1:45 p.m. EDT....
Here's Why Idera Pharmaceuticals, Inc. Is Surging Today
Shares of Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotech advancing novel therapies for skin-related diseases, are getting a bump after the company presented trial results at....
Here's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August
Despite a stronger-than-expected second quarter earnings report, Allergan's (NYSE: AGN) two month long rally came to an abrupt halt in August with the stock losing 9.9% of its value, according to....
Why Biogen Stock Raced Higher In August
Biotech titan Biogen (NASDAQ: BIIB) saw its shares rise by 8.73% last month, according to data from S&P Global Market Intelligence. This healthy march northward was sparked by an encouraging....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 31 août 2017
Le 8 septembre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.On Friday, Allergan (NYSE: AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties should win from....
Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
By late June, Cara Therapeutics, Inc. (NASDAQ: CARA) stock had soared more than 175% year to date. Within a couple of weeks, however, many of those gains had been lost. Cara shares crashed after....
3 Reasons to Buy Allergan plc Stock Right Now
Allergan (NYSE: AGN) is one of the most underappreciated big pharma stocks on the market right now. That's the thought that occurred to me as I listened to Brent Saunders, Allergan's CEO, speak at....
Is Amicus Therapeutics Stock Still a Strong Buy?
According to data from S&P Global Market Intelligence, shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ: FOLD) rose by 6.6% last month. Although the company did provide a bevy of....